Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.30 USD
Change Today -0.80 / -15.69%
Volume 5.0K
DDXSD On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

diadexus inc (DDXSD) Snapshot

Open
$4.56
Previous Close
$5.10
Day High
$4.70
Day Low
$4.30
52 Week High
07/17/14 - $11.40
52 Week Low
06/9/15 - $3.93
Market Cap
16.5M
Average Volume 10 Days
4.2K
EPS TTM
$-1.50
Shares Outstanding
3.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIADEXUS INC (DDXSD)

Related News

No related news articles were found.

diadexus inc (DDXSD) Related Businessweek News

No Related Businessweek News Found

diadexus inc (DDXSD) Details

diaDexus, Inc., a life sciences company, focuses on the development and commercialization of cardiovascular diagnostic products addressing needs in cardiovascular disease. Its products include PLAC ELISA Test and the PLAC Activity Test that are designed to provide information on traditional risk factors, such as cholesterol levels to help identify individuals at risk of suffering a heart attack or stroke. The company’s PLAC ELISA Test is an aid in predicting risk for coronary heart disease (CHD) and ischemic strokes associated with atherosclerosis; and PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) Activity is used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of CHD in patients with no prior history of cardiovascular events. Its pipeline of proprietary biomarkers comprises proADM, proET-1, and proANP for the treatment of heart failure diseases. The company markets its products to various national and regional clinical reference laboratories in the United States, Europe, and internationally. diaDexus, Inc. is headquartered in South San Francisco, California.

41 Employees
Last Reported Date: 03/12/15

diadexus inc (DDXSD) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $100.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $431.8K
Chief Medical Officer
Total Annual Compensation: $117.5K
Compensation as of Fiscal Year 2014.

diadexus inc (DDXSD) Key Developments

diaDexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

diaDexus, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net loss of $1 million for the first quarter of 2015 narrowed from the $4.1 million loss reported for the same quarter last year due to revenue growth from product sales and reduction of operating costs and expenses as described earlier. Total revenues were $5.5 million compared to $5.4 million reported in the first quarter of 2014. This increase was primarily the result of increased sales of the PLAC ELISA Test, partially offset by a decrease in service revenue. Loss from operations was $508,000 against $3,868,000 a year ago. Basic and diluted net loss per share was $0.02 against $0.07 a year ago.

diaDexus, Inc. to Report Q1, 2015 Results on May 12, 2015

diaDexus, Inc. announced that they will report Q1, 2015 results After-Market on May 12, 2015

diaDexus, Inc., Annual General Meeting, Jun 09, 2015

diaDexus, Inc., Annual General Meeting, Jun 09, 2015., at 13:00 Pacific Standard Time. Agenda: To elect Directors; to approve, on an advisory basis, the compensation of the company's named executive officers; to approve a reverse stock split in the range of 1 for 8 to 1 for 15, to be determined by the board of directors in its sole discretion, and a reduction in the number of authorized shares of the company's common stock from 100,000,000 shares to 50,000,000 shares; to approve an amendment to the company's 2012 Equity Incentive Award Plan to (i) increase the number of shares reserved for issuance thereunder by 4,000,000 shares, and (ii) for purposes of Section 162(m) of the Code, prior to giving effect to any reverse stock split; and to ratify the appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DDXSD:US $4.30 USD -0.80

DDXSD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.52 USD +0.44
Alere Inc $53.74 USD +0.99
Quest Diagnostics Inc $72.90 USD +0.38
Roche Holding AG SFr.266.30 CHF +4.30
Siemens AG €91.50 EUR +0.86
View Industry Companies
 

Industry Analysis

DDXSD

Industry Average

Valuation DDXSD Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIADEXUS INC, please visit www.diadexus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.